Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

(CSE: NEON )

N/A UNCHANGED
Last Price Updated: 3:59 PM EST, Dec 13, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open -
Bid (Size) 0.0050 (20,000)
Ask (Size) 0.4000 (2,000)
Prev. Close 0.0100
Today's Range N/A - N/A
52wk Range N/A - N/A
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
NeonMind Announces Plan to Launch 10 Clinics for Innovative Treatments as Mental Health Crisis Grows
Partnered with SRx Health Solutions and BioScript Solutions to Build Out a Network of NeonMind-branded Specialty Mental Health Clinics Across Canada OAKVILLE, ON / ACCESSWIRE / April 12, 2022 /... 
From NeonMind Biosciences Inc.
Via AccessWire
NeonMind to Present at H.C. Wainwright 2nd Annual Psychedelics Virtual Conference
VANCOUVER, BC / ACCESSWIRE / December 2, 2021 / NeonMind Biosciences Inc. (CSE:NEON) (OTCQB:NMDBF) (FRA:6UF) ("NeonMind'' or the "Company"), an integrated drug development and wellness company focused... 
From NeonMind Biosciences Inc.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property

Performance

More News

Read More
NeonMind Announces Successful Completion of Pre-IND Consultation with FDA on Clinical Path for Obesity Drug Candidate NEO-001
From NeonMind Biosciences Inc.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property Product Safety
NeonMind to Participate in Panel Discussion at Lift & Co. Expo's Psychedelics Business Summit on November 19, 2021
From NeonMind Biosciences Inc.
Via AccessWire
Topics Cannabis Intellectual Property
Exposures Cannabis Intellectual Property
NeonMind and SRx Health Solutions Announce Strategic Alliance to Establish Specialty Mental Health Clinics for Interventional Psychiatry Treatments
From NeonMind Biosciences Inc.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property
NeonMind Biosciences Named as a Top Industry Innovator in Inaugural Issue of Psychedelia Magazine
From NeonMind Biosciences Inc.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property
NeonMind Advances Strategy for Specialty Clinic Launch
From NeonMind Biosciences Inc.
Via AccessWire
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
NeonMind Strengthens its Specialty Clinics Advisory Board with Appointment of Mood Disorders and Ketamine Expert Dr. Gustavo Vazquez, MD, PhD.
From NeonMind Biosciences Inc.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property
NeonMind Appoints Ketamine and Neurostimulation Expert Dr. Roumen Milev, MD, PhD to Specialty Clinic Advisory Board
From NeonMind Biosciences Inc.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property
NeonMind Announces Divestiture of Consumer Related and Other Non-Core Assets
From NeonMind Biosciences Inc.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property Product Safety
NeonMind to Present at H.C. Wainwright 23rd Annual Global Investment Conference
From NeonMind Biosciences Inc.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property
NeonMind Announces DTC Eligibility
From NeonMind Biosciences Inc.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property
NeonMind Receives Health Canada Approval for its Functional Mushroom Formulation 'Mindful Blend'
From NeonMind Biosciences Inc.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property
NeonMind Announces Corporate Update and Strategic Reorganization of its Pharmaceutical Division
From NeonMind Biosciences Inc.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property Product Safety
Dr. Sagar Parikh, MD Appointed to NeonMind Specialty Clinics Advisory Board
From NeonMind Biosciences Inc.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property
NeonMind Provides Integrated Drug Development Plan Update for NEO-001 to Treat Obesity
From NeonMind Biosciences Inc.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property
NeonMind Announces Launch of Functional Mushroom Coffees as Dietary Supplements in the US
From NeonMind Biosciences Inc.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property Product Safety
NeonMind to Present at H.C. Wainwright Psychedelics in Psychiatry and Beyond Virtual Conference
Via Newsfile
Topics Intellectual Property
Exposures Intellectual Property
NeonMind Announces Vitasave Will Carry NeonMind Functional Mushroom Products
Via Newsfile
Topics Intellectual Property
Exposures Intellectual Property
NeonMind to Commence Trading on the OTCQB Venture Market
Via Newsfile
Topics Intellectual Property
Exposures Intellectual Property
NeonMind Announces Creation of Medical Clinics Advisory Board to Guide Planning and Operation of Company-Branded Clinics Across Canada
Via Newsfile
Topics Intellectual Property
Exposures Intellectual Property
NeonMind to Present at the Benzinga Global Small Cap Conference
Via Newsfile
Topics Intellectual Property
Exposures Intellectual Property
BTV Explores Investment Options in Life Sciences
Via Newsfile
Exposures COVID-19
NeonMind Announces New Specialty Clinics Division to Deliver Innovative Mental Health Services, Appoints New VP, Corporate Development
Via Newsfile
Topics Death Intellectual Property
Exposures COVID-19 Death Intellectual Property
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.